Ocular Therapeutix (NSDQ:OCUL) said today that it landed a licensing deal with Regeneron (NSDQ:REGN) to develop a sustained-release version of Regeneron’s aflibercept (Eylea), a therapy for wet age-related macular degeneration. The deal will cost Regeneron $10 million up front, and in total could cost the Tarrytown, N.Y.-based biotech $315 million if regulatory and commercialization milestones are met. The terms […]
